NCT03664921View on ClinicalTrials.gov

Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

November 15, 2018

Primary Completion Date

August 17, 2020

Study Completion Date

August 17, 2020

Conditions
Diabetic NeuropathiesNeuropathic PainPain, Chronic
Interventions
DRUG

Omnitram Oral Tablet

Administered three times daily for 28 consecutive days.

DRUG

Placebo Oral Tablet

Administered three times daily for 28 consecutive days.

Trial Locations (4)

63141

St. Louis Clinical Trials, St Louis

78229

Endeavor Clinical Trials, LLC, San Antonio

90703

Core Healthcare Group, Cerritos

92801

Orange County Research Institute, Anaheim

Sponsors

Collaborators (1)

DF/Net Research
All Listed Sponsors
collaborator

DF/Net Research

UNKNOWN

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Syntrix Biosystems, Inc.

INDUSTRY

NCT03664921 - Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy | Biotech Hunter | Biotech Hunter